Avanos Medical, Inc. reports developments as a medical technology company that develops, manufactures and markets medical device solutions for Specialty Nutrition Systems and Pain Management and Recovery. Its news commonly covers operating results, segment growth, enteral feeding products, non-opioid surgical pain and recovery products, infusion pumps, radiofrequency ablation solutions and cryo-pneumatic compression systems.
Company updates also include Medicare payment and regulatory reimbursement developments for ON-Q, AmbIT and Game Ready, collaborations for outpatient and interventional pain workflows, investor conference presentations, cost and transformation initiatives, and governance matters such as board nominations and shareholder agreements.
Avanos Medical, Inc. (NYSE: AVNS) has appointed Moji James as senior vice president & general counsel, effective immediately. With over 25 years of legal experience, James has previously served as chief legal officer at Tmunity Therapeutics and general counsel at Iroko Pharmaceuticals. Her extensive background in healthcare law and compliance is expected to enhance Avanos' strategic direction. CEO Joe Woody praised her qualifications, emphasizing the importance of her role in advancing the company's vision and addressing key healthcare needs.
Avanos Medical (NYSE: AVNS) announced an upcoming presentation by CEO Joe Woody at the Virtual 2021 Raymond James Human Health Innovation Conference on June 22 at 10:40 a.m. ET. A live webcast will be accessible in the Investors section of their website, with an archived version also available. Avanos is dedicated to providing innovative medical device solutions to enhance patient care and reduce opioid dependency.
Avanos Medical reported Q1 2021 results, with net sales of $181 million, unchanged year-over-year. The company experienced a net loss of $8 million, contrasting with a net income of $4 million last year. Adjusted net income rose to $11 million from $8 million. Gross margin decreased to 51% from 57%, primarily due to increased freight costs. The company expects 2021 net sales to increase by 2 to 4% and projects adjusted diluted earnings per share between $1.10 and $1.25. Free cash flow was an outflow of $9 million.
Avanos Medical will host a conference call on May 7, 2021, at 9 a.m. ET, to discuss its financial results for the first quarter of 2021. A news release detailing these results will be issued before market opening that day. The call will be led by CEO Joe Woody and CFO Michael Greiner. Investors can join by dialing 877-240-5772 in the U.S. A replay will be available starting at noon ET on the same day. Avanos Medical focuses on innovative medical solutions, aiming to reduce opioid use and enhance patient recovery.
Avanos Medical, Inc. (NYSE: AVNS) will have CEO Joe Woody present at the Virtual KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at approximately 2 p.m. ET. A live webcast of the presentation can be accessed in the Investors section of Avanos Medical's website, where it will also be archived. Avanos Medical is dedicated to enhancing patient care and reducing opioid use through innovative medical devices.
Avanos Medical (NYSE: AVNS) announced that Michael Greiner, senior vice president and chief financial officer, will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference on March 1 at approximately 3:50 p.m., ET. A live webcast of the presentation will be available on Avanos' Investors section and archived on their website.
Avanos Medical reported Q4 2020 net sales of $185 million, down 3% year-over-year, while full-year sales rose 3% to $715 million. The Q4 net loss was $47 million, compared to a loss of $6 million last year. Adjusted net income for the quarter was $13 million, down from $16 million a year ago. The company implemented a restructuring program projected to yield $7 million in annual savings. Notably, the restructuring led to an overall charge of $25-$30 million. Despite pandemic challenges, the company aims for growth and margin improvement in 2021.
Avanos Medical (NYSE: AVNS) will hold a conference call on Feb. 18, 2021, at 9 a.m. ET, to discuss its fourth quarter and full-year 2020 financial results. A news release detailing these results will be issued before market open that day. The call will be hosted by CEO Joe Woody and CFO Michael Greiner. Investors can join the call by dialing 877-240-5772 or access a live webcast via the Avanos Medical website. A replay will be available starting Feb. 18 at noon ET for one week.
Avanos Medical (NYSE: AVNS) will have CEO Joe Woody present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at approximately 2 p.m. ET. This presentation will be available via a live webcast, including a Q&A session, accessible through the Investors section of Avanos Medical's website and will be archived for later viewing. The company focuses on innovative healthcare solutions aimed at reducing opioid use and improving patient recovery.
Avanos Medical, Inc. (NYSE: AVNS) will present at two virtual investor conferences in November 2020. The Stifel 2020 Virtual Healthcare Conference will take place on Nov. 18 at 10 a.m. ET, featuring CEO Joe Woody. The Stephens Annual Investment Conference is scheduled for Nov. 19 at 8 a.m. ET, with CFO Michael Greiner speaking. Investors can access webcasts of both presentations on the Investors section of the Avanos Medical website. The company focuses on breakthrough medical device solutions to improve patient quality of life.